UNC93B1 and hemophagocytic syndrome: Importantly, anti-TLR9-treated Unc93b1+/3dPld3−/−Pld4−/− mice showed a clinical benefit even though the disease was already severe prior to treatment, indicating that TLR9 blockade might be beneficial long after HLH disease initiation.